The study, published in Scientific Reports, demonstrated that animals injected with synthetic DNA engineered to encode a
specific neutralizing antibody
against the dengue virus were capable of producing the exact antibodies necessary to protect
against disease, without the need for standard antigen - based
vaccination.
On the basis of the current studies as well as previous reports on the use of intradermal immunization
against influenza, hepatitis B, rabies, and other infectious
diseases, 2,3,8 it is becoming clear that use of the intradermal route may at least partially overcome the relatively poor influenza -
specific immune responses seen in certain at - risk populations, particularly the elderly, in whom the immune response in general is known to diminish with age.9 Moreover, in times of shortage, the dose - sparing intradermal approach might be particularly well suited to the young, healthy persons included in the CDC's high - priority group for
vaccination, such as health care workers, as well as to younger, otherwise healthy populations in general.
The scientific work at the HZI Department of Vaccinology and Applied Microbiology includes the elucidation of mechanisms of host responses to infection and
vaccination, discovering new mucosal adjuvants, and developing and validating vaccines
against specific infectious
diseases.